Sueanne Chear

Computational drug repurposing identifies N-acetylglucosamine as a potential therapeutic compound for CLN3 Batten disease

The paper uses computational drug repurposing to identify N-acetylglucosamine as a potential therapy for CLN3 Batten disease, showing it reduces lipofuscin burden in cell models.

Genetic and cellular basis of impaired phagocytosis and photoreceptor degeneration in CLN3 disease.

This study investigates how CLN3 mutations impair phagocytosis and cause photoreceptor degeneration in CLN3 disease using patient-derived cells and a miniswine model.

Lysosomal alterations and decreased electrophysiological activity in CLN3 disease (966 bp deletion, E295K) patient-derived cortical neurons

This study examines CLN3 disease using patient-derived cortical neurons, finding reduced electrophysiological activity and lysosomal alterations.